478010-70-7

Usage

Molecular structure

A complex structure derived from indenone, which includes a hydroxyl group and three methyl substituents.

Type of compound

A chemical compound with potential applications in organic synthesis and pharmaceuticals.

Aromatic ring system

The presence of an aromatic ring system contributes to its unique structure and reactivity.

Functional groups

Contains a hydroxyl group and methyl substituents, which contribute to its versatility in chemical reactions.

Building block

The compound serves as a versatile building block for the preparation of various biologically active molecules.

Hydroxylation pattern

The presence of a hydroxyl group influences its potential for diverse chemical interactions and reactions.

Methyl substitution pattern

The three methyl substituents on the molecule contribute to its unique properties and reactivity.

Industrial and scientific applications

The complex and intriguing chemical properties of 2,3-dihydro-5-hydroxy-3,3,6-trimethylinden-1-one make it valuable for a range of applications in both industries and scientific research.

Upstream product

• 541-47-9 3-Methylbutenoic acid 
• 95-48-7 ortho-cresol 

Downstream Products

• 637013-01-5 N'-(4-amino-6-cyclopropyl-1,3,5-triazin-2-yl)-5-[(3,3,6-trimethyl-2,3-dihydro-1H-inden-5-yl)oxy]-2-furohydrazide 
• 65021-23-0 3,3,6-trimethyl-5-hydroxy-indane 

Relevant academic research and scientific papers

Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist

Gonadotropin releasing hormone (GnRH) plays an important role in the biology of reproduction. The use of GnRH receptor antagonists has been reported in the literature for the treatment of breast, ovarian, and prostate cancers. In this article, we report the synthesis, in vitro characterization, pharmacokinetics, and pharmacodynamics of an orally bioavailable, potent, small molecule GnRH receptor antagonist N-{4,6-dimethoxy-2-[(3-morpholin-4-ylpropyl) amino]pyrimidin-5-yl}-5-[3,3,6-trimthyl-2,3-dihydro-1H-inden-5-yl)oxy] -2-furamide (compound 1).

RADIOLABELED GNRH ANTAGONISTS AS PET IMAGING AGENTS

Provided herein is technology relating to imaging agents for positron emission tomography (PET) and particularly, but not exclusively, to a gonadotropin-releasing hormone (GnRH) antagonist radiolabeled with positron emitting nuclides and to methods of visualizing GnRH receptors in the central nervous system by PET from administration of such compounds to warm-blooded animals for diagnostic purposes.

Non-peptide GnRH agents, pharmaceutical compositions and methods for their use

Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE

Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression o￡ gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.